Category: Healthcare
If successful, data from this preclinical study would be used as part of the support for an Independent New Drug (IND)-filing with the US Food and Drug Administration (FDA) for the use of GBS' Cannabinoid Containing Complex Mixtures (CCCM™) to treat the potentially-fatal Cytokine Release Syndrome associated with COVID-19 and other dangerous hyperinflammatory conditions.
